Trial Profile
A Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients With Moderate-to-Severe Crohn's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs GSK 1070806 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms CDAID
- 25 Feb 2020 Status changed from active, no longer recruiting to completed.
- 25 Feb 2020 Planned End Date changed from 1 Aug 2020 to 1 Jun 2020.
- 31 Dec 2019 Status changed from recruiting to active, no longer recruiting.